Feasibility for Development of a Liposome/LNP Displaying an HIV Env Trimer Protein and Containing/Incorporating an mRNA

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: Timothy R Fouts
Organization: ADVANCED BIOSCIENCE LABORATORIES, INC.
Fiscal Year: 2024
Award: $1,863,405
Funding agency: National Institute of Allergy and Infectious Diseases

Preclinical and Translational Vaccine Development for HIV and Other Candidate Agents (PTVDS): This program will provide NIAID with a broad and flexible range of capabilities that are required for preclinical and translational development support for promising vaccines and related products for HIV and other candidate agents. Contracts under this program will provide the support and services needed for all stages of process and product development, small-scale production, preclinical testing and documentation leading to Investigational New Drug (IND) submissions for Phase I, II, and III clinical testing. These capabilities will allow NIAID to rapidly and efficiently address development and production gaps. This contract will provide support under Task Area C: Feasibility Studies and Early Manufacturability Assessments.

Terms: <AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Antigens><Area><Binding><Clinical Evaluation><Clinical Testing><Contracting Opportunities><Contracts><Coupled><Development><Documentation><Feasibility Studies><Goals><HIV><HIV envelope><HIV envelope protein><HIV vaccine><HIV/AIDS Vaccines><Human Immunodeficiency Viruses><Investigational Drugs><Investigational New Drugs><LAV-HTLV-III><Lipids><Liposomal><Liposomes><Lymphadenopathy-Associated Virus><Membrane><Messenger RNA><Molecular Interaction><NIAID><National Institute of Allergy and Infectious Disease><Phase><Preclinical Testing><Process><Production><Property><Proteins><Reporter Genes><Services><Vaccines><Virus-HIV><clinical test><develop a vaccine><develop vaccines><development of a vaccine><developmental><flexibility><flexible><human immunodeficiency virus vaccine><immunogen><mRNA><manufacturability><membrane structure><nano particle><nano-sized particle><nanoparticle><nanosized particle><pre-clinical><pre-clinical testing><preclinical><product development><programs><research clinical testing><scaffold><scaffolding><vaccine development><vaccine platform>